Paroxysmal Nocturnal Hemoglobinuria (PNH) Global Market Report 2024

Description

“Paroxysmal Nocturnal Hemoglobinuria (PNH) Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on paroxysmal nocturnal hemoglobinuria (pnh) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for paroxysmal nocturnal hemoglobinuria (pnh)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The paroxysmal nocturnal hemoglobinuria (pnh) market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Treatment Type: Medications; Bone Marrow Transplantation; Blood Transfusion; Immunosuppressive Therapy; Other Treatment Types
2) By Diagnosis Type: Flow Cytometry; High-Resolution Mass Spectrometry; Other Diagnosis Types
3) By End Use: Hospitals; Clinics; Other End Users
Companies Mentioned: Pfizer Inc.; Johnson & Johnson Pvt Ltd; F. Hoffmann-La Roche AG.; Novartis AG; Sanofi S.A.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Paroxysmal nocturnal hemoglobinuria (PNH) is an uncommon hematological disorder that is acquired, and it is characterized by the abnormal breakdown of red blood cells (hemolysis) due to a deficiency of certain proteins found on the surface of blood cells. This condition is debilitating and can lead to premature death, as well as impaired blood cell production. PNH manifests through a variety of symptoms, including fatigue, shortness of breath, abdominal pain, and the formation of blood clots known as thrombosis.

The primary approaches to treating paroxysmal nocturnal hemoglobinuria (PNH) involve the use of medications, bone marrow transplantation, blood transfusion, immunosuppressive therapy, and other methods. Medications are substances specially designed and formulated for the diagnosis, treatment, prevention, or alleviation of medical conditions, diseases, or symptoms in both humans and animals. Various diagnostic techniques, such as flow cytometry and high-resolution mass spectrometry, are utilized by a range of end users, including hospitals, clinics, and others.

The paroxysmal nocturnal hemoglobinuria market research report is one of a series of new reports from The Business Research Company that provides paroxysmal nocturnal hemoglobinuria market statistics, including paroxysmal nocturnal hemoglobinuria industry global market size, regional shares, competitors with a paroxysmal nocturnal hemoglobinuria market share, detailed paroxysmal nocturnal hemoglobinuria market segments, market trends and opportunities and any further data you may need to thrive in the paroxysmal nocturnal hemoglobinuria industry. This paroxysmal nocturnal hemoglobinuria market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The paroxysmal nocturnal hemoglobinuria (pnh) market size has grown rapidly in recent years. It will grow from $3.84 billion in 2023 to $4.24 billion in 2024 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to growing demand for paroxysmal nocturnal hemoglobinuria treatment, rising disposable incomes, government initiatives, rising healthcare expenditure.

The paroxysmal nocturnal hemoglobinuria (pnh) market size is expected to see strong growth in the next few years. It will grow to $6.09 billion in 2028 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to aging population, growing demand for self-administered treatments, increasing access to healthcare, increasing prevalence of comorbidities, growing demand for personalized medicine. Major trends in the forecast period include digital health technologies, development of new and innovative treatments,adoption of gene therapy, early intervention.

The growing prevalence of blood and bone marrow disorders is set to be a significant driver for the paroxysmal nocturnal hemoglobinuria (PNH) market's expansion in the coming years. Blood disorders encompass a range of medical conditions that affect the composition, function, and production of blood and its various components. Bone marrow-related disorders, on the other hand, occur when the bone marrow either inadequately produces red blood cells, white blood cells, or platelets or generates blood cells that are flawed or damaged. PNH is intricately linked to both blood disorders and bone marrow-related disorders due to its impact on blood cell production, immune system function, and the bone marrow microenvironment. It is a rare blood disorder closely associated with bone marrow failure diseases, arising from a genetic anomaly that alters the functioning of red blood cells and platelets. For instance, in June 2021, as reported by the Leukemia Foundation, a non-governmental organization based in Australia, over 110,000 individuals in Australia are affected by blood disorders. Projections indicate that the number of Australians with blood disorders will surge to more than 275,000 by 2035. Furthermore, the Cancer Data in Australia 2021 report by the Australian Institute of Health and Welfare (AIHW), a government agency, revealed that over 50 Australians were diagnosed with blood cancer daily in 2021, up from 47 daily diagnoses in 2020. Hence, the increasing incidence of blood disorders and bone marrow-related disorders is a major factor propelling the growth of the paroxysmal nocturnal hemoglobinuria (PNH) market.

The growing requirement for blood transfusions is poised to be a driving force behind the expansion of the paroxysmal nocturnal hemoglobinuria (PNH) market. Blood transfusion is a medical procedure that involves the transfer of blood or blood products from a donor to a recipient. For individuals with paroxysmal nocturnal hemoglobinuria (PNH), blood transfusions can offer temporary relief from the symptoms and complications associated with this condition. For instance, in June 2023, the World Health Organization, an intergovernmental organization headquartered in Switzerland, reported that high-income nations, which account for only 16% of the global population, contributed significantly to blood donations, comprising 40% of the total 118.5 million blood donations made worldwide. Additionally, in December 2022, the Government of Canada reported that the United Kingdom experienced an upsurge in blood donations, with 1.7 million donations made across the country in 2021. Consequently, the escalating demand for blood transfusions is a key factor driving the growth of the paroxysmal nocturnal hemoglobinuria (PNH) market.

The growth of the paroxysmal nocturnal hemoglobinuria (PNH) market is being constrained by the high costs associated with treatments during the projected period. The substantial expenses related to treatment can dissuade pharmaceutical companies from investing in the development of new and more cost-effective PNH treatments. This could potentially decelerate progress and innovation in the field. For example, according to the American Hospital Association, a professional organization, there was a 2.1% increase in hospital prices in the year leading up to February 2022. As a result, the elevated treatment costs are acting as an impediment to the expansion of the paroxysmal nocturnal hemoglobinuria (PNH) market.

Prominent companies operating in the paroxysmal nocturnal hemoglobinuria (PNH) market are dedicated to the development of novel drugs and therapies to maintain their position in the market. Innovation in treatment options is essential in addressing the unique needs of PNH patients, exemplified by EMPAVELI, the first C3-targeted therapy. For instance, in May 2021, Apellis Pharmaceuticals Inc., a US-based biopharmaceutical company, announced the approval of EMPAVELI (pegcetacoplan) by the U.S. Food and Drug Administration (FDA). EMPAVELI represents the first and only targeted C3 therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). It has the potential to significantly enhance the quality of life for PNH patients by increasing hemoglobin levels and reducing the necessity for blood transfusions. EMPAVELI's benefits extend to adults with PNH, including those transitioning from any C5 inhibitor, as well as patients who have not previously received treatment. To further support patients throughout their treatment journey, the company has introduced ApellisAssist, a treatment access and support program. This program offers a comprehensive range of product support services, including assistance with insurance, educational resources, training, and financial aid for eligible patients.

In July 2021, AstraZeneca PLC, a pharmaceutical company headquartered in the UK, completed the acquisition of Alexion Pharmaceuticals Inc. The financial details of the deal were not disclosed. With this strategic move, AstraZeneca solidifies its position as a leader in the development of medications for individuals affected by rare diseases. This acquisition significantly enhances AstraZeneca's scientific footprint in the field of immunology. Alexion Pharmaceuticals Inc., the company acquired by AstraZeneca, is based in the United States and specializes in research, development, and treatment of paroxysmal nocturnal hemoglobinuria (PNH).

Major players in the paroxysmal nocturnal hemoglobinuria (pnh) market are Pfizer Inc., Johnson & Johnson Pvt Ltd, F. Hoffmann-La Roche AG., Novartis AG, Sanofi S.A., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., GE Healthcare, Regeneron Pharmaceuticals Inc., CSL Behring LLC, Biogen Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., Genentech Inc., Shire PLC, Alnylam Pharmaceuticals Inc., Innovent Biologics Inc., Bioverativ Inc., CinnaGen Co, BioCryst Pharmaceuticals, Omeros Corporation, Hansa Biopharma AB, Apellis Pharmaceuticals Inc., Kira Pharmaceuticals Ltd, Akari Therapeutics PLC, RA Pharmaceuticals Inc., C5 Therapeutics Inc.

North America was the largest region in the paroxysmal nocturnal hemoglobinuria (PNH) market in 2023. The regions covered in paroxysmal nocturnal hemoglobinuria (PNH) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the paroxysmal nocturnal hemoglobinuria (PNH) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The paroxysmal nocturnal hemoglobinuria (PNH) market consists of revenues earned by entities by providing services such as gene therapy, stem cell transplant and complete blood count test (CBC). The market value includes the value of related goods sold by the service provider or included within the service offering. The paroxysmal nocturnal hemoglobinuria (PNH) market also includes sales of Eculizumab and Ravulizumab. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r12282

1. Executive Summary

2. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Characteristics

3. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Trends And Strategies

4. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Size and Growth

5.1. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Segmentation

6.1. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Medications
Bone Marrow Transplantation
Blood Transfusion
Immunosuppressive Therapy
Other Treatment Types
6.2. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Flow Cytometry
High-Resolution Mass Spectrometry
Other Diagnosis Types
6.3. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Clinics
Other End Users

7. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Regional And Country Analysis

7.1. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

8.1. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

9.1. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview
9.2. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

10.1. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

11.1. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview
11.2. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

12.1. Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

13.1. Indonesia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

14.1. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview
14.2. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

15.1. Western Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview
15.2. Western Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

16.1. UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

17.1. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

18.1. France Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

19.1. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

20.1. Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

21.1. Eastern Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview
21.2. Eastern Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

22.1. Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

23.1. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview
23.2. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

24.1. USA Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview
24.2. USA Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

25.1. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview
25.2. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

26.1. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview
26.2. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

27.1. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

28.1. Middle East Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview
28.2. Middle East Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

29.1. Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview
29.2. Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Competitive Landscape And Company Profiles

30.1. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Competitive Landscape
30.2. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Johnson & Johnson Pvt Ltd
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. F. Hoffmann-La Roche AG.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Novartis AG
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Sanofi S.A.
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Other Major And Innovative Companies

31.1. Thermo Fisher Scientific Inc.
31.2. Takeda Pharmaceutical Company Limited
31.3. Amgen Inc.
31.4. GE Healthcare
31.5. Regeneron Pharmaceuticals Inc.
31.6. CSL Behring LLC
31.7. Biogen Inc.
31.8. Vertex Pharmaceuticals Incorporated
31.9. Grifols S.A.
31.10. Genentech Inc.
31.11. Shire plc
31.12. Alnylam Pharmaceuticals Inc.
31.13. Innovent Biologics Inc.
31.14. Bioverativ Inc.
31.15. CinnaGen Co

32. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Competitive Benchmarking

33. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

35. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Future Outlook and Potential Analysis

35.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Market In 2028 - Countries Offering Most New Opportunities
35.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Market In 2028 - Segments Offering Most New Opportunities
35.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer